co.don Past Earnings Performance
Past criteria checks 0/6
co.don's earnings have been declining at an average annual rate of -15.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
-15.4%
Earnings growth rate
1.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 10.7% |
| Return on equity | -214.2% |
| Net Margin | -143.5% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Here's Why co.don (ETR:CNW) Can Afford Some Debt
Oct 06
Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?
May 06Will co.don (ETR:CNWK) Spend Its Cash Wisely?
Mar 15Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Long
Feb 08co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.
Jan 04
Revenue & Expenses BreakdownBeta
How co.don makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 10 | -14 | 11 | 0 |
| 31 Mar 22 | 10 | -12 | 11 | 0 |
| 31 Dec 21 | 10 | -9 | 11 | 0 |
| 30 Sep 21 | 8 | -10 | 11 | 0 |
| 30 Jun 21 | 7 | -11 | 10 | 0 |
| 31 Mar 21 | 6 | -13 | 10 | 0 |
| 31 Dec 20 | 6 | -14 | 10 | 0 |
| 30 Sep 20 | 6 | -15 | 11 | 0 |
| 30 Jun 20 | 7 | -16 | 11 | 0 |
| 31 Mar 20 | 7 | -14 | 10 | 0 |
| 31 Dec 19 | 7 | -13 | 10 | 0 |
| 30 Sep 19 | 6 | -11 | 9 | 0 |
| 30 Jun 19 | 6 | -9 | 8 | 0 |
| 31 Mar 19 | 6 | -7 | 8 | 0 |
| 31 Dec 18 | 6 | -6 | 8 | 0 |
| 30 Sep 18 | 6 | -7 | 8 | 0 |
| 30 Jun 18 | 6 | -8 | 8 | 0 |
| 31 Mar 18 | 6 | -8 | 7 | 0 |
| 31 Dec 17 | 6 | -7 | 7 | 0 |
| 30 Sep 17 | 6 | -6 | 6 | 0 |
| 30 Jun 17 | 6 | -5 | 6 | 0 |
| 31 Mar 17 | 6 | -4 | 5 | 0 |
| 31 Dec 16 | 6 | -4 | 5 | 0 |
| 30 Sep 16 | 6 | -3 | 5 | 0 |
| 30 Jun 16 | 6 | -3 | 5 | 0 |
| 31 Mar 16 | 5 | -3 | 4 | 0 |
| 31 Dec 15 | 5 | -3 | 4 | 0 |
Quality Earnings: CNW is currently unprofitable.
Growing Profit Margin: CNW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNW is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare CNW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: CNW has a negative Return on Equity (-214.21%), as it is currently unprofitable.